A phase 1/2a, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-30355 in adult patients with advanced solid tumors harboring TP53 Y220C mutation

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today